Denise Scots-Knight - 11 Sep 2024 Form 4 Insider Report for Mereo BioPharma Group plc (MREO)

Role
Chief Executive Officer, Director
Signature
/s/ Christine Fox, by power of attorney
Issuer symbol
MREO
Transactions as of
11 Sep 2024
Net transactions value
$0
Form type
4
Filing time
13 Sep 2024, 16:49:08 UTC
Previous filing
27 Jun 2024
Next filing
16 Sep 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MREO American Depositary Shares representing Ordinary Shares Options Exercise $0 +188,060 +27% $0.000000 897,578 11 Sep 2024 Direct F1, F2, F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MREO Performance Based Restricted Stock Unit Options Exercise $0 -188,060 -100% $0.000000 0 11 Sep 2024 American Depository Shares 188,060 $0.000000 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.
F2 Represents performance-based restricted stock unit earned under the Issuer's 2019 Employee Incentive Plan (the "Plan"), that vested on September 11, 2024 based on satisfaction of ADS price threshold values over a two year performance period.
F3 Reporting Person also beneficially owns 4 ordinary shares, nominal value of GBP 0.003 per ordinary share, of the Issuer.
F4 Includes 1,200 ADSs jointly owned by Reporting person and her spouse.